Therapy for Stage IV Non–Small Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, Version 2024.3
Abstract
Living guidelines are developed for selected topic areas with rapidly evolving evidence that drives frequent change in recommended clinical practice. Living guidelines are updated on a regular schedule by a standing expert panel that systematically reviews the health literature on a continuous basis, as described in the ASCO Guidelines Methodology Manual . ASCO Living Guidelines follow the ASCO Conflict of Interest Policy Implementation for Clinical Practice Guidelines . Living Guidelines and updates are not intended to substitute for independent professional judgment of the treating clinician and do not account for individual variation among patients. See appendix for disclaimers and other important information ( Appendix 1 and 2 ). Updates are published regularly and can be found at https://ascopubs.org/nsclc-non-da-living-guideline .
Article Details
Journal Info
Journal of Clinical Oncology
Lippincott Williams & Wilkins
Authors (11)
Natasha B. Leighl
Nofisat Ismaila
American Society of Clinical Oncology (ASCO), Alexandria, VA, US
Greg Durm
Indiana University Health, Indianapolis, IN, US
Narjust Florez
Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
Janet Freeman-Daily
The ROS1ders, Seattle, WA
Bruna Pellini
Deebya Raj Mishra
BP Koirala Institute of Health Sciences, Dharan, Nepal
Erin L. Schenk
University of Colorado Anschutz Medical Center, Aurora, CO
Lecia Sequist
Massachusetts General Hospital, Boston, MA
Navneet Singh
Department of Chemistry, Indian Institute of Technology Delhi 1 , Hauz Khas, New Delhi 110016,
Lyudmila Bazhenova
University of California, San Diego, San Diego, CA, US